Karunanayake E H, Hearse D J, Mellows G
Diabetologia. 1976 Oct;12(5):483-8. doi: 10.1007/BF01219512.
The excretion of radioisotope following the administration of three specifically 14C-labelled forms of streptozotocin was investigated in the rat using ureter and bile duct cannulation techniques. The urine collected during the first hour following the administration of the drug contained the highest proportion of injected radioactivity (approximately 34% with (3'-methyl-14C)-streptozotocin and approximately 40% each with (1-14C)-and (2'-14C)-streptozotocin. Over the entire experimental period (6 hours), approximately 70% of the injected radioactivity of (1-14C)- and (2'-14C)-streptozotocin appeared in the urine. With (3'-methyl-14C)-streptozotocin, only 53% of the injected radioactivity appeared in the urine over the same period. In contrast to the high urinary excretion, less than 3% of the injected radioactivity from all three radiolabelled streptozotocin samples appeared in the bile. The in vivo and in vitro metabolism of streptozotocin was also investigated. In addition to substantial amounts of unchanged drug, three radiolabelled metabolites (two major and one minor) were detected in the urine during the 6 hour collection period following the administration of (1-14C)- and (2'-14C)-streptozotocin. In contrast, only unchanged (3'-methyl-14C)-streptozotocin was detected in the urine collected over the same period following the administration of the methyl labelled drug. The two major metabolites were also produced when (1-14C)-and (2'-14C)-streptozotocin were incubated with a rat liver supernatant fraction (100,000 X g). The liver was further demonstrated to be the major site of metabolism in isolated liver perfusion studies in which both (1-14C)- and (2'-14C)-streptozotocin were quantitatively converted to the two major metabolites. The two major metabolites of (1-14C)-streptozotocin, whether produced in vivo or in vitro, were chromatographically homogenous with the two major metabolites formed from (2'-14C)-streptozotocin. Nicotinamide pretreatment had no apparent effect on the urinary excretion of streptozotocin and its metabolites.
采用输尿管和胆管插管技术,在大鼠中研究了给予三种特异性14C标记形式的链脲佐菌素后放射性同位素的排泄情况。给药后第一小时收集的尿液中,注入的放射性物质比例最高((3'-甲基-14C)-链脲佐菌素约为34%,(1-14C)-和(2'-14C)-链脲佐菌素各约为40%)。在整个实验期(6小时)内,(1-14C)-和(2'-14C)-链脲佐菌素注入的放射性物质约70%出现在尿液中。对于(3'-甲基-14C)-链脲佐菌素,在同一时期只有53%注入的放射性物质出现在尿液中。与高尿排泄形成对比的是,所有三种放射性标记的链脲佐菌素样品中,注入的放射性物质不到3%出现在胆汁中。还研究了链脲佐菌素的体内和体外代谢。除了大量未变化的药物外,在给予(1-14C)-和(2'-14C)-链脲佐菌素后6小时收集期内,尿液中检测到三种放射性标记的代谢物(两种主要的和一种次要的)。相比之下,在给予甲基标记药物后同一时期收集的尿液中,只检测到未变化的(3'-甲基-14C)-链脲佐菌素。当(1-14C)-和(2'-14C)-链脲佐菌素与大鼠肝脏上清液组分(100,000×g)一起孵育时,也产生了这两种主要代谢物。在离体肝脏灌注研究中进一步证明肝脏是代谢的主要部位,其中(1-14C)-和(2'-14C)-链脲佐菌素都定量转化为两种主要代谢物。(1-14C)-链脲佐菌素的两种主要代谢物,无论在体内还是体外产生,在色谱上都与由(2'-14C)-链脲佐菌素形成的两种主要代谢物相同。烟酰胺预处理对链脲佐菌素及其代谢物的尿排泄没有明显影响。